A Case Where Switching the End Points for Clinical Trial Interpretation Might Be the Right Choice

JAMA Oncol. 2017 Jun 1;3(6):735-736. doi: 10.1001/jamaoncol.2016.4896.
No abstract available

MeSH terms

  • Aged
  • Aromatase Inhibitors / therapeutic use*
  • Breast Neoplasms / drug therapy*
  • Breast Neoplasms / mortality*
  • Computer Simulation
  • Disease-Free Survival
  • Endpoint Determination / methods*
  • Female
  • Humans
  • Letrozole / therapeutic use*
  • Randomized Controlled Trials as Topic
  • Research Design
  • Survival Rate

Substances

  • Aromatase Inhibitors
  • Letrozole